Compare NTNX & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | TECH |
|---|---|---|
| Founded | 2009 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.6B |
| IPO Year | 2015 | 1995 |
| Metric | NTNX | TECH |
|---|---|---|
| Price | $42.01 | $51.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 11 |
| Target Price | $62.29 | ★ $71.82 |
| AVG Volume (30 Days) | ★ 3.1M | 1.9M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ 227.45 | N/A |
| EPS | ★ 0.57 | 0.49 |
| Revenue | ★ $2,537,927,000.00 | $1,219,635,000.00 |
| Revenue This Year | $13.44 | $2.49 |
| Revenue Next Year | $13.03 | $6.40 |
| P/E Ratio | ★ $72.55 | $109.34 |
| Revenue Growth | ★ 18.11 | 5.23 |
| 52 Week Low | $34.01 | $46.05 |
| 52 Week High | $83.36 | $72.16 |
| Indicator | NTNX | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 40.58 |
| Support Level | $35.23 | $49.55 |
| Resistance Level | $42.19 | $57.37 |
| Average True Range (ATR) | 1.59 | 2.52 |
| MACD | 0.38 | -0.55 |
| Stochastic Oscillator | 95.24 | 8.13 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.